struck contrast iff financi result
compani optim earn call sure wouldv thought top
line miss versu consensu estim albeit line model includ
sequenti deceler legaci organ sale growth would neutral
neg data point instead manag state optim around strong start
five week quarter substanti complet intern
investig briberi alleg drove short squeez share yesterday
despit optim around bia think could risk
sale disappoint ep like insul given cost save leverag
week typic lumpi quarter respect custom order
pattern particularli around holiday period atyp see larg order
push follow quarter surpris see
compani talk revenu growth approach result februari similar
done past three quarter
expect revenu ep estim migrat lower higher time
clear dont expect consensu estim move overnight believ
number move lower street factor variou headwind earn
model total compani organ sale growth
includ earn lower ep estim
ep growth yoy growth previous bodi
note includ full ebit bridg wed note consensu current model
revenu growth ep growth
bottom line even overhang iff briberi investig seemingli
lift result expect mute ep growth reinforc
underweight rate share pt
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
underweight remain concern
frutarom busi legaci believ
limit visibl anticip recoveri
sale growth believ well could
discoveri ahead vi vi process control
get learn frutarom
upsid case base ev/ebitda
multipl upsid case ebitda estim
mm assum trade discount
peer
downsid case base ev/ebitda
multipl downsid case ebitda estim
mm assum trade
discount peer
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
struck contrast iff financi result
compani optim earn call ep expect steer lower
result wouldv thought top line miss versu consensu estim albeit line
model includ sequenti deceler legaci organ sale growth
would neutral neg
data point instead manag state optim around strong start
five week quarter substanti complet intern investig
drove short squeez share yesterday vs note
expect week bp benefit three divis add bp
organ sale growth versu previou estim wed previous model
bp benefit legaci
despit optim around bia think could risk sale
disappoint ep like insul typic lumpi quarter respect
custom order pattern particularli around holiday period atyp
see larg order push follow quarter surpris see
compani talk revenu growth approach result februari similar
done past three quarter said know manag confirm
earn low end guidanc rang given expect
increment mm cost synergi mention also
degre benefit oper leverag week think
flexibl reach ep target
disclosur iff file exacerb concern underli financi
weaken strengthen far deem forens
account notabl item iff give us paus respect
cash flow non-cor benefit cash quarter believ like
inflat underli figur includ new factor program quarter
acceler benefit cash flow sequenti unwind cross currenc
swap deriv instrument also includ addit disclosur around
potenti goodwil impair frutarom compani fail achiev
anticip growth revenu expect synergi applic interest rate
increas yesterday call manag mention unlik frutarom would
impair uncommon occurr late weve seen least three
impair chpc coverag past six month pg gillett edgewel
wet shave infant busi asset
even overhang iff briberi investig seemingli lift result
expect mute ep growth reinforc underweight rate
share overhang frutarom briberi investig lift weve
ask would take us get construct short
wed see frutarom organ sale growth consist grow mid-singl digit
rang new weak spot impli faster grow adjac gain scale
organ sale legaci grow least fast peer success complet
frutarom site optim work without increment execut hiccup first point
still hard time understand organ growth could acceler mid-
singl digit rang model organ sale growth full
year legaci model organ sale growth
believ industri averag integr frutarom
cost synergi work date center procur heavi lift plant
closur skew believ risk profil project much higher
expect revenu ep estim migrat lower higher time
clear dont expect consensu estim move overnight believ number
move lower street factor variou headwind earn
model total compani organ sale growth includ
model growth growth lap week believ
iff expect growth lap tast volum eros
transitori frutarom issu also confid signific ramp cross-
sell benefit mm ytd mm end
understand still includ pt sale growth top line algorithm
earn lower ep estim ep growth yoy
growth previous embed assumpt limit oper
leverag constant currenc sale growth believ on-going product
cost save off-set inflat raw materi inflat peopl cost etc
includ ebit headwind lap cash flow hedg gain mm incent comp
reset mm currenc transact mm lap week mm
off-set frutarom cost synergi mm model ebit growth
yoy benefit below-the-lin item ep growth note
consensu current model revenu growth ep growth
lower ep growth yoy lower
rais price target share sole due fact peer
group multipl re-rat higher sinc august last chang price target
price target base ebitda multipl ebitda estim
mm assum trade discount peer previou price
target assum discount peer ebitda multipl previou
ebitda estim mm
ebit impactebit ebit ebit growth sale hedg comp transact total adjust adjust ebit growth ep ep growth barclay flavor fragranc
lauren lieberman herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
